Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE‐LY trial

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 5, 2015-05 ,pp. : 699-707

John Wiley & Sons Inc

Access to resources Recommend Favorite

Re: Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 27, Iss. 2, 2018-02 ,pp. : 243-243

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of non‐vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 11, 2015-11 ,pp. : 1341-1348

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

By Deitelzweig Steve   Amin Alpesh   Jing Yonghua   Makenbaeva Dinara   Wiederkehr Daniel   Lin Jay   Graham John  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1163-1168

Informa Healthcare

Access to resources Recommend Favorite

Bleeding risk during oral anticoagulation therapy for atrial fibrillation

By Gallego Pilar   Lip Gregory Y. H.   Lane Deirdre A.  

EP-Europace, Vol. 15, Iss. 6, 2013-06 ,pp. : 773-774

Oxford University Press

Access to resources Recommend Favorite